Voriconazole Tablet, Film Coated
NDC Package 60687-968-21

11-digit billing NDC: 60687096821 · Billing unit: EA · 30 EA per package

Package Information

Voriconazole tablets are contraindicated in patients with known hypersensitivity to voriconazole or its excipients. This formulation utilizes a tablet, film coated delivery system. Marketed by American Health Packaging, this product is identified by NDC 60687-968 and is authorized under FDA application ANDA206837.

Identification & Billing

NDC Package Code
60687-968-21
Package Description
30 BLISTER PACK in 1 CARTON / 1 TABLET, FILM COATED in 1 BLISTER PACK (60687-968-11)
Product Code
11-Digit Billing Format
60687096821
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Voriconazole
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Voriconazole tablets are contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Refer to the prescribing information for other azole antifungal agents.Concomitant use of voriconazole tablets with the interacting drugs described and listed below in this section are a guide and not considered a comprehensive list of all possible drugs that may be contraindicated with voriconazole tablets.1. Concomitant use of voriconazole tablets are contraindicated with drugs that are highly dependent on CYP3A4 for metabolism, and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7)]: EplerenoneErgot alkaloids (e.g., ergotamine, dihydroergotamine)FinerenoneIvabradineLurasidoneNaloxegolPimozideQuinidineRifabutin [see Clinical Pharmacology (12.3)] Sirolimus [see Clinical Pharmacology (12.3)] TolvaptanVenetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)]. Voclosporin2. Concomitant use of voriconazole tablets are contraindicated with drugs and herbal products that induce CYP2C19, CYP2C9, and/or CYP3A4 and for which significantly reduced voriconazole plasma concentrations may be associated with loss of efficacy [see Drug Interactions (7)]: CarbamazepineEfavirenzConcomitant use with efavirenz dosages of 400 mg every 24 hours or higher is contraindicated [see Clinical Pharmacology (12.3)]. Long-acting barbituratesRifabutinRifampinRitonavirConcomitant use with high-dose ritonavir (400 mg every 12 hours) is contraindicated. Concomitant use with low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole tablets [see Clinical Pharmacology (12.3)] . St. John’s Wort [see Clinical Pharmacology (12.3)]

Regulatory & Marketing

Labeler Name
American Health Packaging
Product Type
Human Prescription Drug
FDA Application #
ANDA206837
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-27-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60687-968-21 identifies a specific commercial package of 30 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack (60687-968-11) of Voriconazole, a human prescription drug labeled by American Health Packaging. This tablet, film coated is formulated for oral use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by American Health Packaging on August 27, 2026. The current certification is valid through December 31, 2027.

How is this American Health Packaging product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60687096821. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60687-968-21
11-Digit CMS (5-4-2)
60687-0968-21

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.